Advertisement
Screener

CANDEL THERAPEUTICS, INC. (CADL) Interest Income (Expense), Net

2.8 / 5 stars · 68/120 Roast Me

CANDEL THERAPEUTICS, INC. Interest Income (Expense), Net

CANDEL THERAPEUTICS, INC. (CADL) reported Interest Income (Expense), Net of $102.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.

Discontinued › Income Statement › Other Income

us-gaap:InterestIncomeExpenseNet · last filed 2023-05-11

  • CANDEL THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2023-03-31 was $102.00K.
  • CANDEL THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2022-03-31 was -$175.00K.
Period endInterest Income (Expense), Net 3 month
2023-03-31$102.00K
10-Q · filed 2023-05-11
2022-03-31-$175.00K
10-Q · filed 2023-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Aura Biosciences, Inc. (AURA)United States$0.639B-5.61